Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - pilocarpine hydrochloride, quantity: 40 mg/ml - eye drops, solution - excipient ingredients: boric acid; sodium citrate dihydrate; purified water; benzalkonium chloride; hypromellose - in the treatment of glaucoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - pilocarpine hydrochloride, quantity: 20 mg/ml - eye drops, solution - excipient ingredients: sodium citrate dihydrate; purified water; boric acid; hypromellose; benzalkonium chloride - in the treatment of glaucoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - pilocarpine hydrochloride, quantity: 10 mg/ml - eye drops, solution - excipient ingredients: sodium citrate dihydrate; boric acid; hypromellose; purified water; sodium chloride; benzalkonium chloride - in the treatement of glaucoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fluorometholone -

Australia - English - Department of Health (Therapeutic Goods Administration)

landauer radiopharmaceuticals pty ltd - gallium (67ga) citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

landauer radiopharmaceuticals pty ltd - gallium (67ga) citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

landauer radiopharmaceuticals pty ltd - thallous(201tl) chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

landauer radiopharmaceuticals pty ltd - thallous(201tl) chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

landauer radiopharmaceuticals pty ltd - gallium (67ga) citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - carmustine, quantity: 100 mg - injection, powder for - excipient ingredients: - indications as at 16 december 1985: carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: 1. malignant glioma. 2. multiple myeloma: in combination with prednisone. 3. hodgkin's disease: as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 4. non-hodgkins lymphomas: as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.